CYCLOBENZAPRINE HYDROCHLORIDE TABLET , LIDOCAINE AND PRILOCAINE, (Cyclopak) Nursing Considerations

What is the generic name?

CYCLOBENZAPRINE HYDROCHLORIDE TABLET , LIDOCAINE AND PRILOCAINE,

What is the Trade Name for CYCLOBENZAPRINE HYDROCHLORIDE TABLET , LIDOCAINE AND PRILOCAINE,?

Cyclopak

What are the Indications for CYCLOBENZAPRINE HYDROCHLORIDE TABLET , LIDOCAINE AND PRILOCAINE,?

• INDICATIONS AND USAGE Lidocaine and prilocaine cream (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on: – normal intact skin for local analgesia. – genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lidocaine and prilocaine cream is not recommended in any clinical situation when penetration or migration beyond the tympanic membrane into the middle ear is possible because of the ototoxic effects observed in animal studies (see WARNINGS ).
• INDICATIONS AND USAGE Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.

References: https://open.fda.gov/